Mice lacking NCF1 exhibit reduced growth of implanted melanoma and carcinoma tumors

PloS One
Tiina KelkkaRikard Holmdahl

Abstract

The NADPH oxidase 2 (NOX2) complex is a professional producer of reactive oxygen species (ROS) and is mainly expressed in phagocytes. While the activity of the NOX2 complex is essential for immunity against pathogens and protection against autoimmunity, its role in the development of malignant tumors remains unclear. We compared wild type and Ncf1 (m1J) mutated mice, which lack functional NOX2 complex, in four different tumor models. Ncf1 (m1J) mutated mice developed significantly smaller tumors in two melanoma models in which B16 melanoma cells expressing a hematopoietic growth factor FLT3L or luciferase reporter were used. Ncf1 (m1J) mutated mice developed significantly fewer Lewis Lung Carcinoma (LLC) tumors, but the tumors that did develop, grew at a pace that was similar to the wild type mice. In the spontaneously arising prostate carcinoma model (TRAMP), tumor growth was not affected. The lack of ROS-mediated protection against tumor growth was associated with increased production of immunity-associated cytokines. A significant increase in Th2 associated cytokines was observed in the LLC model. Our present data show that ROS regulate rejection of the antigenic B16-luc and LLC tumors, whereas the data do not support a role...Continue Reading

References

Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·N M GreenbergJ M Rosen
Dec 15, 2000·Medical Oncology·K HellstrandP Naredi
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Dec 4, 2002·Nature Genetics·Peter OlofssonRikard Holmdahl
Jan 7, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sergei KusmartsevDmitry I Gabrilovich
Aug 18, 2004·Proceedings of the National Academy of Sciences of the United States of America·Malin HultqvistRikard Holmdahl
Feb 16, 2005·Laboratory Investigation; a Journal of Technical Methods and Pathology·Alexei V SalnikovKristofer Rubin
Feb 19, 2008·Cancer Research·Sylvia LuxenUlla G Knaus
Apr 25, 2008·Blood·Fumiko Marttila-IchiharaSirpa Jalkanen
Jun 9, 2009·Clinical Reviews in Allergy & Immunology·Steven M Holland
Jun 26, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kristin HagenowRikard Holmdahl
Aug 27, 2009·Free Radical Research·Tullia MaraldiGabriele Hakim
Feb 10, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Srinivas NagarajDmitry I Gabrilovich
Sep 24, 2010·Proceedings of the National Academy of Sciences of the United States of America·Marina D KraaijKyra A Gelderman
Jul 7, 2011·Antioxidants & Redox Signaling·Lina M OlssonRikard Holmdahl
Aug 21, 2012·Antioxidants & Redox Signaling·Rikard HolmdahlLiselotte Bäckdahl

❮ Previous
Next ❯

Citations

May 2, 2014·Archives of Biochemistry and Biophysics·Feng Liu-SmithFrank L Meyskens
Dec 20, 2015·Immunological Reviews·Rikard HolmdahlKajsa Wing
Jun 16, 2015·PloS One·Maarten A LigtenbergRolf Kiessling
Mar 30, 2017·The Journal of Experimental Medicine·David C ThomasKenneth G C Smith
Oct 3, 2018·The Journal of Pathology·Anna MartnerKristoffer Hellstrand
Apr 14, 2015·Developmental Psychobiology·Mark S BlumbergCarlos Del Rio-Bermudez
Dec 15, 2020·Oxidative Medicine and Cellular Longevity·Hanna Grauers WiktorinAnna Martner
Jul 15, 2021·Communications Biology·Jianghong ZhongRikard Holmdahl

❮ Previous
Next ❯

Methods Mentioned

BETA
genetic modifications
Transgenic
PCR
electrophoresis
PMA
flow cytometry

Software Mentioned

CellQuest
GraphPad Prism
FlowJo
Flowing
SPSS
Sigma Plot
LightCycler
FACS Diva

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.